3,545 AbbVie Inc. $ABBV Shares Purchased by IRON Financial LLC

Key Points

• IRON Financial LLC increased its AbbVie position by 122.4% in the third quarter, purchasing 3,545 additional shares and bringing its holdings to 6,441 shares valued at approximately $1.685 million. Institutional investors collectively own 70.23% of AbbVie.
• AbbVie received FDA approval for a more convenient subcutaneous induction regimen of SKYRIZI for Crohn’s disease, potentially supporting growth as the company offsets Humira’s patent loss. The company’s dividend remains a defensive appeal, with a quarterly payout of $1.73 per share and a 2.4% yield.
• Despite mostly positive analyst ratings and a “Moderate Buy” consensus, investors face elevated expectations: shares trade near their 52-week high at a premium valuation, while analysts are watching upcoming earnings and guidance closely.

IRON Financial LLC raised its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 122.4% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 6,441 shares of the company's stock after purchasing an additional 3,545 shares during the period. IRON Financial LLC's holdings in AbbVie were worth $1,685,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ABBV. Corient Private Wealth LP purchased a new stake in shares of AbbVie during the second quarter worth $559,736,000. Legal & General Group Plc purchased a new position in shares of AbbVie in the second quarter worth about $2,905,952,000. Jupiter Topco LLC purchased a new position in shares of AbbVie in the second quarter worth about $1,560,354,000. Diamant Asset Management Inc. lifted its stake in shares of AbbVie by 21,649.0% in the first quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company's stock worth $798,456,000 after buying an additional 3,654,351 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in AbbVie during the second quarter worth about $817,473,000. Hedge funds and other institutional investors own 70.23% of the company's stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. FDA approved a subcutaneous induction regimen for SKYRIZI in adults with moderately to severely active Crohn’s disease. The on-body injector provides a more convenient administration option throughout treatment, while Phase 3 data showed superior clinical remission and endoscopic response versus placebo with no new safety risks. The approval could strengthen SKYRIZI’s commercial position and support AbbVie’s post-Humira growth strategy. FDA approves subcutaneous SKYRIZI induction for Crohn’s disease
• Positive Sentiment: AbbVie’s dividend remains a key defensive attraction. Analysts and financial commentators point to the company’s ability to maintain shareholder payouts despite Humira’s patent loss, supported by growth from SKYRIZI, RINVOQ and other newer products. AbbVie’s dividend after Humira’s patent cliff
• Neutral Sentiment: AbbVie’s Phase 3 INTREPID trial for lutikizumab in hidradenitis suppurativa met its primary endpoint and eight ranked secondary endpoints, including reduced pain and fewer flares. However, reported efficacy was viewed by some analysts as underwhelming relative to competing treatments, leaving the drug’s eventual commercial opportunity uncertain. AbbVie reports Phase 3 INTREPID results for lutikizumab
• Negative Sentiment: Investors are approaching next week’s earnings report cautiously. Erste Group lowered its 2026 EPS estimate to $13.90 from $14.00, slightly below the roughly $13.94 consensus, while a Zacks preview said AbbVie lacks the usual indicators for a likely earnings beat. With the shares trading near their 52-week high and at a premium valuation, results and guidance may need to be strong to sustain momentum. AbbVie earnings preview

AbbVie Trading Up 0.0%

Shares of ABBV stock opened at $285.66 on Monday. The company's 50-day moving average price is $266.33 and its 200-day moving average price is $242.01. The stock has a market cap of $504.70 billion, a price-to-earnings ratio of 80.69, a PEG ratio of 1.30 and a beta of 0.24. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $291.40.

AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie's quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities research analysts predict that AbbVie Inc. will post 13.93 EPS for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie's payout ratio is presently 195.48%.

Analyst Ratings Changes

ABBV has been the subject of several research reports. Leerink Partners upped their price objective on shares of AbbVie from $245.00 to $279.00 and gave the company an "outperform" rating in a research note on Wednesday, August 5th. Argus raised their target price on shares of AbbVie from $250.00 to $270.00 in a research note on Tuesday, August 4th. Oppenheimer raised their target price on shares of AbbVie from $244.00 to $258.00 and gave the stock a "neutral" rating in a research note on Monday, August 3rd. Barclays boosted their target price on AbbVie from $300.00 to $325.00 and gave the stock an "overweight" rating in a report on Wednesday. Finally, Wolfe Research upgraded AbbVie from a "peer perform" rating to an "outperform" rating and upped their price target for the company from $235.00 to $300.00 in a research report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $279.86.

Insider Activity at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company's stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.06% of the company's stock.

AbbVie Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.